Canada Markets open in 5 hrs 40 mins

Sernova Corp. (PSH.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.5565+0.0295 (+5.60%)
As of 08:27AM CET. Market open.
Full screen
Previous Close0.5270
Bid0.5265 x 1000000
Ask0.5565 x 1000000
Day's Range0.5265 - 0.5565
52 Week Range0.5265 - 1.5900
Avg. Volume5,684
Market Cap147.111M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes

    Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential study participationTransplantation of islets into the enhanced 10-channel Cell Pouch is anticipated in early 2023Company continues to anticipate first interim safety/efficacy data from second cohort in 2023 LONDON, Ontario, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced to

  • GlobeNewswire

    Sernova to Participate in the Stifel Healthcare Conference

    LONDON, Ontario, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be presenting at the upcoming Stifel Healthcare Conference being held in-person in New York, NY on November 15-16, 2022. Company management will also be participating in one-on-one investor meetings at the conference. Stifel Healthcare Conference Date:9:45AM, November 15, 2022Presenter:Dr. Philip Toleikis, Pres

  • GlobeNewswire

    Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

    Sernova plans to begin enrollment of second cohort in the coming weeks and implant multiple patients with the enhanced capacity 10-channel Cell Pouch before the end of 2022Positive interim results from patients in the first cohort informed the islet dose and density threshold optimizations for the second cohortExpedited enrollment is anticipated with Sernova’s engagement of an experienced clinical trial patient recruitment agency and the Company expects to report interim data in 2023Results from